MarketCap
Facebook
X
Telegram
ADC Therapeutics SA Market Cap | ADCT
As of October 22, 2026 ADC Therapeutics SA has a market cap of $ 191 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap ADC Therapeutics SA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 M | 106 M | 89.1 M | 107 M | 1.22 B | 2.19 B | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.19 B | 89.1 M | 642 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Exicure
XCUR
|
29 M | $ 1.01 | 1.3 % | $ 6.36 M |  USA |
 |
Cellectis S.A.
CLLS
|
335 M | $ 0.97 | -2.17 % | $ 97.3 M |  France |
 |
AbCellera Biologics
ABCL
|
962 M | $ 12.24 | 4.53 % | $ 3.66 B |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 58.84 | -0.14 % | $ 7.87 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 55.21 | -2.18 % | $ 10.6 B | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 29.37 | -3.04 % | $ 1.95 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.64 M | $ 3.76 | -3.22 % | $ 45.9 M |  Israel |
 |
Jaguar Health
JAGX
|
956 K | $ 2.28 | -13.31 % | $ 5.32 M | USA |
 |
Protalix BioTherapeutics
PLX
|
174 M | $ 2.57 | -2.65 % | $ 202 M | Israel |
 |
uniQure N.V.
QURE
|
626 M | $ 22.69 | -0.11 % | $ 1.3 B |  Niderland |
 |
Stoke Therapeutics
STOK
|
2.01 B | $ 25.68 | -3.49 % | $ 1.52 B | USA |
 |
Xencor
XNCR
|
892 M | $ 25.16 | 0.88 % | $ 1.87 B | USA |
 |
Annexon
ANNX
|
769 M | $ 3.86 | 0.78 % | $ 599 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 1.89 | -0.02 % | $ 3.11 M | Israel |
 |
Incyte Corporation
INCY
|
19.5 B | $ 113.44 | -2.72 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
2.04 B | $ 12.83 | 3.38 % | $ 15.5 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
651 M | $ 9.86 | -1.1 % | $ 793 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
125 B | $ 524.52 | 1.92 % | $ 134 B | USA |
 |
AbbVie
ABBV
|
400 B | $ 284.8 | -1.45 % | $ 504 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 31.87 | -2.89 % | $ 4.05 B | USA |
 |
Altimmune
ALT
|
318 M | $ 2.23 | -3.04 % | $ 196 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.18 | -3.46 % | $ 801 M | Canada |
 |
Axon Enterprise
AXON
|
30.6 B | $ 402.6 | 2.54 % | $ 31.4 B | USA |
 |
Oncternal Therapeutics
ONCT
|
27.3 M | - | -24.12 % | $ 1.56 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
125 M | $ 2.08 | 0.48 % | $ 118 M | USA |
 |
Burford Capital Limited
BUR
|
2.78 B | $ 3.05 | -0.65 % | $ 668 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
999 M | $ 13.17 | 0.77 % | $ 1.18 B | USA |
 |
Seagen
SGEN
|
26.3 B | - | - | $ 42.2 B | USA |
 |
Codexis
CDXS
|
111 M | $ 1.29 | 4.88 % | $ 112 M | USA |
 |
Cullinan Management
CGEM
|
898 M | $ 14.89 | 0.4 % | $ 897 M | USA |
 |
Compugen Ltd.
CGEN
|
196 M | $ 2.12 | -0.93 % | $ 198 M | Israel |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
13.5 M | - | - | $ 26.5 M | USA |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 3.81 | 1.06 % | $ 467 M | USA |
 |
Cellectar Biosciences
CLRB
|
7.49 M | $ 1.28 | 4.07 % | $ 3.34 M | USA |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 0.96 | 1.81 % | $ 10.8 M | USA |
 |
Collegium Pharmaceutical
COLL
|
1.4 B | $ 22.92 | -1.36 % | $ 725 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 4.29 | -3.05 % | $ 57.1 M | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
528 K | - | -8.77 % | $ 12.4 M | Israel |
 |
Curis
CRIS
|
9.48 M | $ 0.39 | -1.9 % | $ 5.13 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
318 M | $ 10.05 | -1.76 % | $ 794 M | USA |
 |
Histogen
HSTO
|
3.21 M | - | 31.6 % | $ 2.12 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 25.33 | 3.73 % | $ 3.84 B | USA |
 |
Achieve Life Sciences
ACHV
|
126 M | $ 6.51 | 1.31 % | $ 284 M | USA |
 |
ImmunoGen
IMGN
|
1.02 B | - | - | $ 7.92 B | USA |
 |
Denali Therapeutics
DNLI
|
2.41 B | $ 18.68 | -1.32 % | $ 3.23 B | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.71 | 2.29 % | $ 86.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
4.11 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 37.18 | 1.47 % | $ 2.16 B | USA |